结缔组织病相关间质性肺疾病的临床相关生物标志物。
Clinically Relevant Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease.
机构信息
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan.
Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, University of Michigan.
出版信息
Immunol Allergy Clin North Am. 2023 May;43(2):411-433. doi: 10.1016/j.iac.2023.01.012. Epub 2023 Mar 3.
Abstract
Interstitial lung disease (ILD) complicates connective tissue disease (CTD) with variable incidence and is a leading cause of death in these patients. To improve CTD-ILD outcomes, early recognition and management of ILD is critical. Blood-based and radiologic biomarkers that assist in the diagnosis CTD-ILD have long been studied. Recent studies, including -omic investigations, have also begun to identify biomarkers that may help prognosticate such patients. This review provides an overview of clinically relevant biomarkers in patients with CTD-ILD, highlighting recent advances to assist in the diagnosis and prognostication of CTD-ILD.
摘要
间质性肺病（ILD）是结缔组织病（CTD）的并发症，其发病率存在差异，也是此类患者的主要致死原因。为改善 CTD-ILD 患者的预后，早期识别和管理ILD 至关重要。长期以来，人们一直在研究用于辅助诊断 CTD-ILD 的基于血液和影像学的生物标志物。最近的研究，包括组学研究，也开始鉴定可能有助于此类患者预后判断的生物标志物。本文综述了 CTD-ILD 患者中具有临床意义的生物标志物，重点介绍了有助于 CTD-ILD 诊断和预后判断的最新进展。
相似文献
1
Clinically Relevant Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease.
Immunol Allergy Clin North Am. 2023 May;43(2):411-433. doi: 10.1016/j.iac.2023.01.012. Epub 2023 Mar 3.
2
Clinically Relevant Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease.
Rheum Dis Clin North Am. 2024 Aug;50(3):439-461. doi: 10.1016/j.rdc.2024.03.007.
3
The Spectrum of Interstitial Lung Disease in Connective Tissue Disease.
J Thorac Imaging. 2016 Mar;31(2):65-77. doi: 10.1097/RTI.0000000000000191.
4
Comparison of characteristics of connective tissue disease-associated interstitial lung diseases, undifferentiated connective tissue disease-associated interstitial lung diseases, and idiopathic pulmonary fibrosis in Chinese Han population: a retrospective study.
Clin Dev Immunol. 2013;2013:121578. doi: 10.1155/2013/121578. Epub 2013 Sep 19.
5
Risk of primary graft dysfunction following lung transplantation in selected adults with connective tissue disease-associated interstitial lung disease.
J Heart Lung Transplant. 2021 May;40(5):351-358. doi: 10.1016/j.healun.2021.01.1391. Epub 2021 Jan 23.
6
Identification and management of connective tissue disease-associated interstitial lung disease: evidence-based Japanese consensus statements.
Expert Rev Respir Med. 2023 Jan;17(1):71-80. doi: 10.1080/17476348.2023.2176303. Epub 2023 Feb 20.
7
Serum Rcn3 level is a potential diagnostic biomarker for connective tissue disease-associated interstitial lung disease and reflects the severity of pulmonary function.
BMC Pulm Med. 2023 Feb 19;23(1):68. doi: 10.1186/s12890-023-02360-4.
8
Mean pulmonary arterial pressure as a prognostic indicator in connective tissue disease associated with interstitial lung disease: a retrospective cohort study.
BMC Pulm Med. 2016 Apr 19;16(1):55. doi: 10.1186/s12890-016-0207-3.
9
Comparative analysis of connective tissue disease-associated interstitial lung disease and interstitial pneumonia with autoimmune features.
Clin Rheumatol. 2020 Feb;39(2):575-583. doi: 10.1007/s10067-019-04836-3. Epub 2019 Nov 22.
10
Impact of a systematic evaluation of connective tissue disease on diagnosis approach in patients with interstitial lung diseases.
Medicine (Baltimore). 2020 Jan;99(4):e18589. doi: 10.1097/MD.0000000000018589.
引用本文的文献
1
[Connective tissue disease-associated interstitial lung diseases : A pattern-based approach to diagnosis].
Radiologie (Heidelb). 2025 Aug 22. doi: 10.1007/s00117-025-01492-4.
2
Serum KL-6 and SP-D: Markers of Lung Function in Autoimmune-Related Interstitial Lung Diseases.
Int J Mol Sci. 2025 Jan 27;26(3):1091. doi: 10.3390/ijms26031091.
3
The clinical value of KL-6 for predicting the occurrence and severity of connective tissue disease-associated interstitial lung disease is not affected by CTD type or treatment.
PeerJ. 2024 Aug 8;12:e17792. doi: 10.7717/peerj.17792. eCollection 2024.
本文引用的文献
1
The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements.
Lancet Rheumatol. 2020 Feb;2(2):e71-e83. doi: 10.1016/S2665-9913(19)30144-4. Epub 2020 Jan 14.
2
Association of Serum Biomarkers With Pulmonary Involvement of Rheumatoid Arthritis Interstitial Lung Disease: From KORAIL Cohort Baseline Data.
J Rheum Dis. 2021 Oct 1;28(4):234-241. doi: 10.4078/jrd.2021.28.4.234.
3
Validation of Proposed Criteria for Progressive Pulmonary Fibrosis.
Am J Respir Crit Care Med. 2023 Jan 1;207(1):69-76. doi: 10.1164/rccm.202201-0124OC.
4
High-resolution computed tomography of the chest for the screening, re-screening and follow-up of systemic sclerosis-associated interstitial lung disease: a EUSTAR-SCTC survey.
Clin Exp Rheumatol. 2022 Oct;40(10):1951-1955. doi: 10.55563/clinexprheumatol/7ry6zz. Epub 2022 Jun 30.
5
Diagnostic Accuracy of Chest Radiography for Detecting Fibrotic Interstitial Lung Disease.
Ann Am Thorac Soc. 2022 Nov;19(11):1934-1937. doi: 10.1513/AnnalsATS.202112-1377RL.
6
Identification of biomarkers by machine learning classifiers to assist diagnose rheumatoid arthritis-associated interstitial lung disease.
Arthritis Res Ther. 2022 May 19;24(1):115. doi: 10.1186/s13075-022-02800-2.
7
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47. doi: 10.1164/rccm.202202-0399ST.
8
KL-6 as a Biomarker of Interstitial Lung Disease Development in Patients with Sjögren Syndrome: A Retrospective Case-Control Study.
J Inflamm Res. 2022 Apr 8;15:2255-2262. doi: 10.2147/JIR.S352085. eCollection 2022.
9
Automated quantification system predicts survival in rheumatoid arthritis-associated interstitial lung disease.
Rheumatology (Oxford). 2022 Nov 28;61(12):4702-4710. doi: 10.1093/rheumatology/keac184.
10
The role of precision medicine in interstitial lung disease.
Eur Respir J. 2022 Sep 7;60(3). doi: 10.1183/13993003.02146-2021. Print 2022 Sep.
Zotero 插件